These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 15144849

  • 1. Following the leader: fibrillization of alpha-synuclein and tau.
    Frasier M, Wolozin B.
    Exp Neurol; 2004 Jun; 187(2):235-9. PubMed ID: 15144849
    [No Abstract] [Full Text] [Related]

  • 2. alpha-Synuclein: a potent inducer of tau pathology.
    Geddes JW.
    Exp Neurol; 2005 Apr; 192(2):244-50. PubMed ID: 15755542
    [No Abstract] [Full Text] [Related]

  • 3. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases.
    Goedert M, Spillantini MG, Serpell LC, Berriman J, Smith MJ, Jakes R, Crowther RA.
    Philos Trans R Soc Lond B Biol Sci; 2001 Feb 28; 356(1406):213-27. PubMed ID: 11260802
    [Abstract] [Full Text] [Related]

  • 4. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
    Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM.
    Exp Neurol; 2004 Jun 28; 187(2):279-88. PubMed ID: 15144854
    [Abstract] [Full Text] [Related]

  • 5. Initiation and synergistic fibrillization of tau and alpha-synuclein.
    Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM.
    Science; 2003 Apr 25; 300(5619):636-40. PubMed ID: 12714745
    [Abstract] [Full Text] [Related]

  • 6. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases.
    Lee VM, Giasson BI, Trojanowski JQ.
    Trends Neurosci; 2004 Mar 25; 27(3):129-34. PubMed ID: 15036877
    [Abstract] [Full Text] [Related]

  • 7. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions.
    Popescu A, Lippa CF, Lee VM, Trojanowski JQ.
    Arch Neurol; 2004 Dec 25; 61(12):1915-9. PubMed ID: 15596612
    [Abstract] [Full Text] [Related]

  • 8. [Neuropathology of tauopathies and synucleinopathies, and neuroanatomy of sleep disorders: meeting the challenge].
    Hauw JJ, Hausser-Hauw C, Duyckaerts C.
    Rev Neurol (Paris); 2003 Nov 25; 159(11 Suppl):6S59-70. PubMed ID: 14646802
    [Abstract] [Full Text] [Related]

  • 9. Interface between tauopathies and synucleinopathies: a tale of two proteins.
    Galpern WR, Lang AE.
    Ann Neurol; 2006 Mar 25; 59(3):449-58. PubMed ID: 16489609
    [Abstract] [Full Text] [Related]

  • 10. Neuropathology of primary restless leg syndrome: absence of specific tau- and alpha-synuclein pathology.
    Pittock SJ, Parrett T, Adler CH, Parisi JE, Dickson DW, Ahlskog JE.
    Mov Disord; 2004 Jun 25; 19(6):695-9. PubMed ID: 15197711
    [Abstract] [Full Text] [Related]

  • 11. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau.
    Williams DR.
    Intern Med J; 2006 Oct 25; 36(10):652-60. PubMed ID: 16958643
    [Abstract] [Full Text] [Related]

  • 12. Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology.
    Newman J, Rissman RA, Sarsoza F, Kim RC, Dick M, Bennett DA, Cotman CW, Rohn TT, Head E.
    Acta Neuropathol; 2005 Aug 25; 110(2):135-44. PubMed ID: 15986225
    [Abstract] [Full Text] [Related]

  • 13. Pathological tau: a loss of normal function or a gain in toxicity?
    Trojanowski JQ, Lee VM.
    Nat Neurosci; 2005 Sep 25; 8(9):1136-7. PubMed ID: 16127446
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Brief update on different roles of tau in neurodegeneration.
    Ittner A, Ke YD, van Eersel J, Gladbach A, Götz J, Ittner LM.
    IUBMB Life; 2011 Jul 25; 63(7):495-502. PubMed ID: 21698753
    [Abstract] [Full Text] [Related]

  • 16. Transgenic zebrafish as a novel animal model to study tauopathies and other neurodegenerative disorders in vivo.
    Paquet D, Schmid B, Haass C.
    Neurodegener Dis; 2010 Jul 25; 7(1-3):99-102. PubMed ID: 20173336
    [Abstract] [Full Text] [Related]

  • 17. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton.
    Esposito A, Dohm CP, Kermer P, Bähr M, Wouters FS.
    Neurobiol Dis; 2007 Jun 25; 26(3):521-31. PubMed ID: 17408955
    [Abstract] [Full Text] [Related]

  • 18. Pathogenic effects of alpha-synuclein aggregation.
    Lundvig D, Lindersson E, Jensen PH.
    Brain Res Mol Brain Res; 2005 Mar 24; 134(1):3-17. PubMed ID: 15790525
    [Abstract] [Full Text] [Related]

  • 19. Overview of protein aggregation in single, double, and triple neurodegenerative brain amyloidoses.
    Trojanowski JQ, Mattson MP.
    Neuromolecular Med; 2003 Mar 24; 4(1-2):1-6. PubMed ID: 14528048
    [No Abstract] [Full Text] [Related]

  • 20. Toward a molecular neuropsychiatry of neurodegenerative diseases.
    Cummings JL.
    Ann Neurol; 2003 Aug 24; 54(2):147-54. PubMed ID: 12891666
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.